Progress in intrauterine administration of autologous hCG-activated peripheral blood mononuclear cells for repeated implantation failure treatment
10.3760/cma.j.cn101441-20211130-00528
- VernacularTitle:hCG共培养自体PBMC宫腔灌注治疗反复种植失败的研究进展
- Author:
Qingyi WANG
1
;
Xiaoxuan ZHAO
;
Jianing SUN
;
Xiaofang LIU
;
Xiaoling FENG
Author Information
1. 黑龙江中医药大学第一临床医学院，哈尔滨 150040
- Publication Type:Journal Article
- Keywords:
Recurrent implantation failure;
Peripheral blood mononuclear cell;
Human chorionic gonadotropin;
Endometrial receptivity;
Intrauterine administration
- From:
Chinese Journal of Reproduction and Contraception
2023;43(1):90-95
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, in vitro fertilization and embryo transfer (IVF-ET) improves the pregnancy rates in patients with recurrent implantation failure (RIF). However, some patients did not get pregnant successfully after IVF-ET. Improving the pregnancy rates in patients with RIF becomes a difficult problem to be solved. Intrauterine administration of autologous human chorionic gonadotropin (hCG)-activated peripheral blood mononuclear cell (PBMC) is a new treatment to improve pregnancy outcome and plays an important role in improving endometrial receptivity and intrauterine microenvironments. This article reviews the application of intrauterine administration of autologous hCG-activated PBMC in RIF, in order to discuss the mechanism of improving the pregnancy outcome of RIF.
